AtriCure, Inc.
About AtriCure, Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $534.5M
- Net income
- -$11.4M
- Total assets
- $654.2M
- Market cap
- $1.4B
- Gross margin
- 75.0%
- Operating margin
- -1.8%
- Net margin
- -2.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $534.5M
- Cost of revenue
- $133.7M
- Gross profit
- $400.8M
- Operating expenses
- $410.2M
- Operating income
- -$9.4M
- Income tax
- $1.3M
- Net income
- -$11.4M
- EPS (basic)
- $-0.24
- EPS (diluted)
- $-0.24
Balance sheet
- Total assets
- $654.2M
- Current assets
- $322.5M
- Total liabilities
- $162.2M
- Current liabilities
- $81.5M
- Shareholders’ equity
- $491.9M
Cash flow
- Operating cash flow
- $57.3M
- Investing cash flow
- -$14.6M
- Financing cash flow
- $1.2M
- Net cash flow
- $44.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-0.24
- Shares outstanding
- 51.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 5, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.4M in FY2025.
- Revenue grew 159% from FY2020 to FY2025.
- Gross margin of 75.0%, net margin -2.1%.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AtriCure, Inc..
Write a review
News about AtriCure, Inc.
News & sentiment via Polygon.io
